Gala­pa­gos seeks 's­trate­gic op­tion­s' for Jy­s­e­le­ca as JAK in­hibitor sales dis­ap­point again

Gala­pa­gos is as­sess­ing “var­i­ous strate­gic op­tions” with Jy­s­e­le­ca, the JAK in­hibitor that once in­spired block­buster pro­jec­tions but re­peat­ed­ly dis­ap­point­ed.

The Bel­gian biotech at­trib­uted the move to the EU’s re­cent rec­om­men­da­tions to lim­it the use of JAK in­hibitors, not­ing ma­jor side ef­fects such as ma­lig­nan­cy, ma­jor ad­verse car­dio­vas­cu­lar events, se­ri­ous in­fec­tions, ve­nous throm­boem­bolism and even death in some pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER